Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study

Area of Science:

• Cardiovascular Pharmacology
• Endothelial Function Research
• Hypertension Therapeutics

Background:

• Vascular endothelial dysfunction is a predictor of atherosclerosis.
• Reversing endothelial dysfunction alongside blood pressure reduction may improve hypertension prognosis.
• Nebivolol, a vasodilating beta-blocker, was hypothesized to improve endothelial dysfunction.

Purpose of the Study:

• To compare the effects of nebivolol and atenolol on endothelial function in hypertensive patients.
• To investigate nebivolol's potential to improve endothelial dysfunction.

Main Methods:

• Double-blind, crossover study comparing nebivolol/bendroflumethiazide and atenolol/bendroflumethiazide in 12 hypertensive patients.
• Forearm venous occlusion plethysmography used to assess endothelium-dependent nitric oxide release via acetylcholine and N(G)-monomethyl-L-arginine (L-NMMA) infusions.
• Endothelium-independent pathway assessed using sodium nitroprusside.

Main Results:

• Both nebivolol/bendroflumethiazide and atenolol/bendroflumethiazide equally lowered blood pressure.
• Nebivolol/bendroflumethiazide significantly increased vasodilatory response to acetylcholine (435+/-27%, P<0.001).
• Nebivolol/bendroflumethiazide improved endothelium-dependent vasoconstriction to L-NMMA (-54+/-5%, P<0.001), while atenolol/bendroflumethiazide did not.
• No significant difference in response to sodium nitroprusside between groups.

Conclusions:

• Nebivolol/bendroflumethiazide enhanced both stimulated and basal endothelial nitric oxide release.
• Atenolol/bendroflumethiazide did not affect nitric oxide bioactivity despite similar blood pressure reduction.
• Nebivolol may provide superior vascular protection in hypertension management compared to atenolol.